From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Clinical data
AHFS/ International Drug Names
Routes of
ATC code
Legal status
Legal status
  • unapproved, never marketed
CAS Number
PubChem CID
Chemical and physical data
Formula C20H27NO4
Molar mass 345.43 g/mol
3D model (JSmol)
Chirality Racemic mixture

Bevantolol (INN) was a drug candidate for angina and hypertension that acted as both a beta blocker and a calcium channel blocker.[1][2] It was discovered and developed by Warner-Lambert[3] but in January 1989 the company announced that it had withdrawn the New Drug Application; the company's chairman said: "Who needs the 30th beta blocker?"[4] As of 2016 it wasn't marketed in the US, UK, or Europe and the authors of a Cochrane review could find no product monograph for it.[5]


  1. ^ Frishman, WH; Goldberg, RJ; Benfield, P (January 1988). "Bevantolol. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in hypertension and angina pectoris". Drugs. 35 (1): 1–21. doi:10.2165/00003495-198835010-00001. PMID 2894292. 
  2. ^ Vaughan Williams, EM (July 1987). "Bevantolol: a beta-1 adrenoceptor antagonist with unique additional actions". Journal of clinical pharmacology. 27 (7): 450–60. doi:10.1002/j.1552-4604.1987.tb03049.x. PMID 2888789. 
  3. ^ McPherson, Edwin M. (2007). Pharmaceutical Manufacturing Encyclopedia (3rd ed.). Burlington: Elsevier. pp. 618–619. ISBN 9780815518563. 
  4. ^ "Warner-Lambert Pipeline Narrowed to 40 Active Research Compounds". Pink Sheet. 30 January 1989. 
  5. ^ Wong, GW; Boyda, HN; Wright, JM (10 March 2016). "Blood pressure lowering efficacy of beta-1 selective beta blockers for primary hypertension". The Cochrane Database of Systematic Reviews. 3: CD007451. doi:10.1002/14651858.CD007451.pub2. PMID 26961574.